• Erin L St Onge and Shannon A Miller.
• University of Florida College of Pharmacy, Orlando Campus, 2725 S Binion Rd, Apopka, FL 32703-8504, USA. stonge@cop.ufl.edu
• Expert Opin Biol Ther. 2010 May 1; 10 (5): 801-6.

Importance Of The FieldDespite the wide array of treatments available, a significant number of patients with type 2 diabetes continue to remain uncontrolled. The discovery of the incretin hormones and their role in glucose homeostasis has brought about a new class of medications called the glucagon-like peptide-1 (GLP-1) analogs. This new class of medications provides the benefits of weight loss as well as a lack of hypoglycemia. However, the currently available agents require once or twice daily injections.Areas Covered In This ReviewRelevant literature will be discussed on albiglutide, a new GLP-1 analog in Phase III clinical trials. Several clinical trials examining the use of albiglutide as combination therapy are currently ongoing.What The Reader Will GainTo date, results of clinical trials suggest that albiglutide may provide a more attractive dosing profile compared with the currently available GLP-1 analogs.Take Home MessageThe results of ongoing trials will help define the role of albiglutide in treating patients with type 2 diabetes.

23 keywords...

hide…